| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 119 |
| 1 | IPILIMUMAB | 69 |
| 2 | CARBOPLATIN | 67 |
| 3 | PACLITAXEL | 52 |
| 4 | PEMETREXED DISODIUM | 20 |
| 5 | BEVACIZUMAB | 19 |
| 6 | DURVALUMAB | 18 |
| 7 | OXALIPLATIN | 12 |
| 8 | PEMETREXED | 12 |
| 9 | TREMELIMUMAB | 12 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEMIPLIMAB-RWLC | 6 | 0.0029 |
| 1 | TREMELIMUMAB | 12 | 0.0027 |
| 2 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 3 | IPILIMUMAB | 69 | 0.0016 |
| 4 | NIVOLUMAB | 119 | 0.0012 |
| 5 | NALDEMEDINE | 2 | 0.0012 |
| 6 | DURVALUMAB | 18 | 0.0008 |
| 7 | HYALURONATE SODIUM | 1 | 0.0007 |
| 8 | TALIMOGENE LAHERPAREPVEC | 1 | 0.0006 |
| 9 | LEVOLEUCOVORIN | 2 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 81 | 0.0017 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 120 | 0.0012 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 18 | 0.0008 |
| 4 | Platinum-based Drug [EPC] | 89 | 0.0003 |
| 5 | Microtubule Inhibitor [EPC] | 53 | 0.0003 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 7 | Thyroid Hormone Synthesis Inhibitor [EPC] | 2 | 0.0002 |
| 8 | CD30-directed Immunoconjugate [EPC] | 2 | 0.0002 |
| 9 | Lipid-based Polyene Antifungal [EPC] | 2 | 0.0002 |